Lupin targets $250 million in quarterly US sales in 3-4 years

Pharmaceutical giant Lupin is confident of surpassing $1 billion in US sales in the next few years. In an interview with CNBC-TV18, Ramesh Swaminathan, the company's Executive Director, Global CFO & Head of Corporate Affairs, said the company will be able to hit a quarterly sales run rate of $250 million in the US in 3-4 years from $200 million now.

Lupin expects a substantial contribution to its US sales from the respiratory portfolio, with anticipated revenues reaching around $300 million.

The company is working aggressively to reach margin of 20-23% soon, he said. The company's last quarter margin was at 18.7%.